Registered Kenya · PPB

IMEG 500MG TABLETS

IMEGLIMIN HYDROCHLORIDE

H2022/CTD10896/24350 EACH FILM COATED TABLET CONTAINS: IMEGLIMIN HYDROCHLORIDE 500MG GENERIC/BIOSIMILARS

What it does

Imeglimin is a medication used to help control blood sugar levels in people with type 2 diabetes.

Commonly used for: type 2 diabetes (diabetes mellitus), blood sugar control

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2022/CTD10896/24350
Registration date
-
Expiry date
2028 November 21
Status
Registered
Active ingredient
IMEGLIMIN HYDROCHLORIDE
Strength
-
Pack size
BLISTER PACKS OF 3 X 10’S, PACKED IN A UNIT BOXES.
Therapeutic class
GENERIC/BIOSIMILARS
Manufacturer / MAH
Dawa
Applicant / LTR
DAWA LIMITED
Country of origin
LOCAL
Manufacturer location
Baba Dogo Rd, Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:22:34 · updated 2026-09-15 02:22:02

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Imeglimin is a medication used to help control blood sugar levels in people with type 2 diabetes.

What it treats

  • type 2 diabetes (diabetes mellitus)
  • blood sugar control

How it works

Imeglimin helps the body use insulin better and reduces the amount of sugar produced by the liver.

Who it's for

This medication is for adults with type 2 diabetes who need help managing their blood sugar levels.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: imeglimin

BNF-referenced

Imeglimin is an antidiabetic agent that belongs to a novel class of medications used in the management of type 2 diabetes mellitus. It is designed to improve glycemic control by targeting multiple pathways that contribute to insulin resistance and impaired glucose metabolism. Its unique mechanism of action sets it apart from other antihyperglycemic agents, making it a potential option for patients who require more comprehensive management of their diabetes.

Indications

  • Type 2 diabetes mellitus
  • Impaired glucose tolerance
  • Hyperglycemia in conjunction with diet and exercise

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines.

Mechanism of action

Imeglimin works by improving insulin sensitivity and enhancing pancreatic beta-cell function. It acts on the liver, muscle, and adipose tissue to promote glucose uptake and utilization while reducing hepatic glucose production. This dual action helps to lower blood glucose levels effectively. Additionally, imeglimin modulates mitochondrial function, which may contribute to its beneficial effects on glucose homeostasis.

Pharmacodynamics

Imeglimin exhibits its pharmacodynamic effects through the modulation of glucose metabolism pathways. By enhancing insulin sensitivity and promoting glucose-dependent insulin secretion, it helps to lower fasting and postprandial blood glucose levels. The drug also has potential benefits in reducing weight gain associated with other antidiabetic medications, although further studies are needed to fully understand its long-term effects on body weight.

Pharmacokinetics

Imeglimin is absorbed following oral administration, with peak plasma concentrations typically occurring within a few hours. It has a moderate bioavailability, and its pharmacokinetic profile indicates a relatively short half-life, necessitating multiple daily dosing in clinical use. The drug is primarily eliminated through renal excretion, with minimal hepatic metabolism, making it suitable for patients with mild to moderate hepatic impairment but caution is advised in those with renal dysfunction.

Pregnancy

There are no adequate data from the use of imeglimin in pregnant women, therefore its use is not recommended during pregnancy.

Breast-feeding

It is not known whether imeglimin is excreted in human milk. Caution should be exercised when using imeglimin during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: imeglimin

PubChem CID 24812808

Molecular formula: C6H13N5

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.